Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Core Insights - Skye Bioscience, Inc. presented findings on nimacimab, a potential first-in-class monoclonal antibody for obesity treatment, at a recent conference, highlighting its efficacy and safety profile when combined with other therapies [1][2][4] Group 1: Nimacimab's Mechanism and Efficacy - Nimacimab is designed to be a peripherally-restricted CB1 receptor inhibitor, minimizing neuropsychiatric side effects associated with previous CB1-targeting drugs [3] - The studies indicated that nimacimab, when combined with lower doses of incretin agonists, could maintain a favorable safety profile while achieving significant efficacy [2][6] - In combination with suboptimal doses of tirzepatide, nimacimab resulted in weight loss of 39% and 46% respectively, demonstrating its additive effects [6] Group 2: Long-term Treatment and Maintenance - The weight loss effects of nimacimab were durable even after treatment discontinuation, with a significant reduction in weight rebound (approximately 80% blunted) [6] - Nimacimab can serve as a maintenance therapy following the discontinuation of tirzepatide, enhancing weight loss outcomes [6] Group 3: Clinical Development and Strategy - Skye is conducting a Phase 2a clinical trial for nimacimab in obesity, assessing its combination with a GLP-1R agonist (Wegovy®) [4] - The company's strategy focuses on developing next-generation therapeutics that modulate G-protein coupled receptors, aiming for clinical and commercial differentiation [4]